Table 4.
Comparative analysis of the HAMA reduction in the different genders, drugs, and genotypes in the case group
| Factors | The reduction of HAMA | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||
| 1 week | 2 week | 4 week | 8 week | |||||||||
|
|
|
|
|
|||||||||
| X±s | F | P | X±s | F | P | X±s | F | P | X±s | F | P | |
| Sex | ||||||||||||
| Male | 3.39±3.06 | 6.71±4.16 | 11.10±4.60 | 12.19±7.60 | ||||||||
| Female | 3.31±2.23 | 0.020 | 0.886 | 6.42±3.34 | 0.137 | 0.712 | 9.69±4.05 | 2.293 | 0.125 | 12.41±6.42 | 0.022 | 0.884 |
| Drug | ||||||||||||
| Esc | 3.44±2.77 | 6.76±3.67 | 10.64±4.38 | 12.66±7.01 | ||||||||
| Ven | 3.19±2.07 | 0.257 | 0.613 | 6.16±3.49 | 0.692 | 0.408 | 9.40±4.01 | 2.169 | 0.144 | 11.91±6.46 | 0.307 | 0.581 |
| Gene (Esc) | ||||||||||||
| AA | 3.18±1.99 | 6.27±3.04 | 9.73±3.90 | 11.09±6.99 | ||||||||
| AG | 2.37±3.25 | 6.67±4.11 | 11.07±4.82 | 12.96±6.91 | ||||||||
| GG | 3.67±2.56 | 0.122 | 0.885 | 7.14±3.50 | 0.214 | 0.808 | 10.57±4.13 | 0.366 | 0.695 | 13.10±7.37 | 0.333 | 0.718 |
| Gene (Ven) | ||||||||||||
| AA | 3.50±2.26 | 7.00±2.10 | 9.50±2.43 | 10.33±1.37 | ||||||||
| AG | 2.90±2.53 | 5.60±4.13 | 9.30±4.16 | 11.70±7.01 | ||||||||
| GG | 3.41±1.37 | 0.349 | 0.708 | 6.53±3.09 | 0.514 | 0.602 | 9.47±4.46 | 0.010 | 0.990 | 11.91±6.46 | 0.308 | 0.737 |
Note. Esc, escitalopram; Ven, venlafaxine, One-way ANOVA.